Trials / Terminated
TerminatedNCT04472897
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2556286 in Healthy Adult Participants
A Randomised, Double Blind (Sponsor Unblinded), Placebo-controlled, First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Oral Doses and the Food Effect of GSK2556286 in Healthy Adult Participants
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This first time in human (FTIH) study assesses the safety, tolerability, and pharmacokinetics (PK) of single and multiple increasing doses of GSK2556286. It also includes food effect cohorts to evaluate how food influences the PK of GSK2556286. The findings will help determine appropriate dosing for future clinical studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK2556286 | GSK2556286 will be administered. |
| DRUG | Placebo | Placebo will be administered |
Timeline
- Start date
- 2020-10-30
- Primary completion
- 2024-11-06
- Completion
- 2024-11-06
- First posted
- 2020-07-16
- Last updated
- 2025-05-11
Locations
2 sites across 2 countries: Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT04472897. Inclusion in this directory is not an endorsement.